Blood test may spare some transplant patients from chemo

NCT ID NCT06954805

Recruiting now Disease control Sponsor: Jennifer Amengual Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a blood test (ctDNA) can help doctors choose the right treatment for people with a type of lymphoma that happens after an organ transplant (PTLD). About 30 participants will be split into low-risk and high-risk groups. Low-risk patients will get only the targeted drug rituximab, while high-risk patients will receive stronger chemotherapy (R-EPOCH). The goal is to see if the blood test can guide treatment to be both effective and less toxic.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm lymphoma lymphoproliferative syndrome post-transplant lymphoproliferative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA LYMPHOMA, B-CELL

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States

Contact Email: •••••@•••••
Stanford Medical Center
NOT_YET_RECRUITING

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.